Solid BiosciencesSLDB
SLDB
About: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Employees: 100
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
240% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 15
187% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 15
101% more capital invested
Capital invested by funds: $145M [Q4 2024] → $292M (+$146M) [Q1 2025]
39% more funds holding
Funds holding: 90 [Q4 2024] → 125 (+35) [Q1 2025]
10.83% more ownership
Funds ownership: 90.92% [Q4 2024] → 101.75% (+10.83%) [Q1 2025]
0% more call options, than puts
Call options by funds: $714K | Put options by funds: $714K
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
39%
upside
Avg. target
$15.50
116%
upside
High target
$20
179%
upside
8 analyst ratings
8 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Yigal Nochomovitz | 95%upside $14 | Buy Initiated | 26 Jun 2025 |
HC Wainwright & Co. Arthur He | 179%upside $20 | Buy Reiterated | 17 Jun 2025 |
JMP Securities Silvan Tuerkcan | 109%upside $15 | Market Outperform Reiterated | 6 Jun 2025 |
Cantor Fitzgerald Kristen Kluska | 123%upside $16 | Overweight Assumed | 22 May 2025 |
Chardan Capital Geulah Livshits | 109%upside $15 | Buy Maintained | 19 May 2025 |
Financial journalist opinion
Based on 5 articles about SLDB published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - CHARLESTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a clinical stage life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-501, the Company's novel, AAV-based investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT).
Positive
Seeking Alpha
2 weeks ago
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)
Solid Biosciences is approaching key catalysts in DMD gene therapy, with SGT-003 showing promising early safety and efficacy signals. The evolving DMD landscape, especially safety concerns with competitors, enhances the appeal of Solid's muscle-tropic vector and unique R16/R17 domains. Despite significant dilution and ongoing losses, Solid's strong cash position supports its pipeline through 2027, justifying an upgrade from Hold to Buy.
Neutral
PRNewsWire
2 weeks ago
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm
PHILADELPHIA , July 10, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating Solid Biosciences Inc. (NASDAQ: SLDB) on behalf of the company's shareholders. Since September 2024, shares of Solid Biosciences' stock have declined in value from a trading price of over $10.00 per share to a current trading price of less than $6.00 per share, a decline of over 40% in value.
Neutral
GlobeNewsWire
3 weeks ago
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA - - Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - - Expands Solid's clinical pipeline to include first cardiac indication with urgent unmet medical need - CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) and clinical trial application (CTA) by Health Canada for SGT-501, a novel gene therapy approach for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), a highly malignant, arrhythmogenic channelopathy caused by genetic mutations that impact the ryanodine receptor (RYR2) in cardiac muscle.
Neutral
GlobeNewsWire
4 weeks ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 105,330 restricted stock units (“RSUs”) to seven newly hired employees.
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (“RSUs”) to two newly hired employees.
Neutral
GlobeNewsWire
2 months ago
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference
CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D.
Neutral
GlobeNewsWire
2 months ago
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
- Duchenne (SGT-003) : Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT (SGT-501): FDA IND on track for submission first half of 2025 - - Cash: Company ended first quarter 2025 with $306.9 million in cash, cash equivalents, investments and available-for-sale securities; Solid has anticipated cash runway into the first half of 2027 - CHARLESTOWN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision, next generation, genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
2 months ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees.
Neutral
GlobeNewsWire
2 months ago
Solid Biosciences to Participate at The Citizens Life Sciences Conference
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET.
Charts implemented using Lightweight Charts™